Stocks Health care AVIR
NASDAQ · Health careAtea Pharmaceuticals, Inc. (AVIR)
It posted a net loss of $155.4M. At September 30, 2026 it held $97.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Atea Pharmaceuticals, Inc.
- Net worth
- Atea Pharmaceuticals, Inc. has a market value (market cap) of $353.7M at the latest share price, and shareholders' equity of $175.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2021 revenue was $351.4M (+622.5% year on year), with net income of $121.2M.
- Cash flow
- In fiscal 2025 operations used $132M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Atea Pharmaceuticals, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Atea Pharmaceuticals, Inc. does
Atea Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AVIR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$158.3M | -$1.94 | n/a |
| 2024 | n/a | -$168.4M | -$2.00 | n/a |
| 2023 | n/a | -$136M | -$1.63 | n/a |
| 2022 | n/a | -$115.9M | -$1.39 | -$122.9M |
| 2021 | $351.4M | $121.2M | $1.37 | -$87M |
| 2020 | $48.6M | -$10.9M | -$0.51 | $296.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Atea Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 9, 2026
- October 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026
- June 22, 2026
- May 12, 2026
- May 12, 2026
- May 6, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Atea Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 18, 2026 | Murphy Polly A.Director | Exercised options | 29,600 | - |
| June 18, 2026 | Polsky BruceDirector | Exercised options | 29,600 | - |
| June 18, 2026 | Adams Jerome M.Director | Exercised options | 29,600 | - |
| June 18, 2026 | Duncan Barbara GayleDirector | Exercised options | 29,600 | - |
| June 18, 2026 | Berger Franklin MDirector | Exercised options | 29,600 | - |
| June 18, 2026 | Lucidi BrunoDirector | Exercised options | 29,600 | - |
| May 18, 2026 | Murphy Polly A.Director | Bought | 6,100 | $25.4K |
| March 11, 2026 | Corcoran AndreaSee Remarks | Exercised options | 60,000 | $74.4K |
Who owns AVIR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | May 6, 2026 |
| Jean-Pierre Sommadossi13G, passive with 1 related filers | 10.1% | May 14, 2025 |
| Leonard Braden Michael13G, passive with 1 related filers | 9.9% | February 9, 2026 |
| Tang Capital Management, LLC13G, passive with 5 related filers | 6% | October 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 125 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 12,004,064 | +53,292 |
| BlackRock, Inc. | 8,720,077 | +284,640 |
| BML Capital Management, LLC | 6,952,330 | -106,327 |
| Tang Capital Management LLC | 4,814,700 | 0 |
| Vanguard Capital Management LLC | 2,964,862 | -281,262 |
| Bain Capital Life Sciences Investors, LLC | 2,075,639 | -284,999 |
| Geode Capital Management, LLC | 1,958,435 | +210,729 |
| State Street Corp | 1,652,399 | -42,236 |
| Two Sigma Investments, LP | 1,506,697 | -357,467 |
| Dimensional Fund Advisors LP | 1,299,515 | +44,031 |
| Renaissance Technologies LLC | 1,131,200 | -35,200 |
| Rosalind Advisors, Inc. | 1,070,550 | -101,305 |
| Jpmorgan Chase & Co | 945,918 | +5,761 |
| Northern Trust Corp | 755,239 | +170,214 |
| Morgan Stanley | 719,514 | -11,506 |
| Vanguard Portfolio Management LLC | 630,185 | +72,606 |
| Charles Schwab Investment Management Inc | 610,607 | +13,898 |
| Goldman Sachs Group Inc | 530,856 | -57,607 |
| Vanguard Fiduciary Trust Co | 469,801 | -14,904 |
| CM Management, LLC | 355,000 | 0 |
Insiders
12 insiders reported holding 3,086,778 shares in total, about $13.6M at the last price.
| Holder | Shares |
|---|---|
| Corcoran AndreaSee Remarks | 823,576 |
| Sommadossi Jean-PierrePresident, CEO, and Chairman, Director | 767,830 |
| Berger Franklin MDirector | 536,097 |
| Lucidi BrunoDirector | 142,350 |
| Hammond Janet MJChief Development Officer | 127,665 |
| Polsky BruceDirector | 124,806 |
| Murphy Polly A.Director | 121,745 |
| Horga Maria ArantxaChief Medical Officer | 96,086 |
| Duncan Barbara GayleDirector | 92,350 |
| Adams Jerome M.Director | 92,350 |
Questions about AVIR
What does Atea Pharmaceuticals, Inc. do?
Atea Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as AVIR. Its shares trade on NASDAQ under the ticker AVIR.
What is Atea Pharmaceuticals, Inc.'s net worth?
Atea Pharmaceuticals, Inc. has a market value (market cap) of $353.7M at the latest share price, and shareholders' equity of $175.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Atea Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $155.4M.
When did Atea Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Atea Pharmaceuticals, Inc.'s next earnings report?
Atea Pharmaceuticals, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AVIR with
Follow AVIR
Get an email when Atea Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Atea Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.